Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial-Reference-Cited by-同舟云学术

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

Published:2016-05 Issue:5 Volume:17 Page:632-641
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mir Olivier,Cropet Claire,Toulmonde Maud,Cesne Axel Le,Molimard Mathieu,Bompas Emmanuelle,Cassier Philippe,Ray-Coquard Isabelle,Rios Maria,Adenis Antoine,Italiano Antoine,Bouché Olivier,Chauzit Emmanuelle,Duffaud Florence,Bertucci François,Isambert Nicolas,Gautier Julien,Blay Jean-Yves,Pérol David

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Advances in the treatment of gastrointestinal stromal tumours;Judson;Ann Oncol,2007

2. Gastrointestinal stromal tumors: pathology and prognosis at different sites;Miettinen;Semin Diagn Pathol,2006

3. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines;Nishida;Gastric Cancer,2016

4. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence;Joensuu;J Clin Oncol,2015

5. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST;Wozniak;Clin Cancer Res,2014

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

2. Efficacy of Trametinib in Neurofibromatosis Type 1–Associated Gastrointestinal Stromal Tumors: A Case Report;JCO Precision Oncology;2024-08

3. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review;Therapeutic Drug Monitoring;2024-04-30

4. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents;Cell Communication and Signaling;2024-04-15

5. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-04-13